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Abstract 
Introduction: Renal Cell Carcinoma (RCC) is the most common kidney-originated neoplasm, which can be 
aggressive with high metastatic potential. It is reported that RCC can recur or metastasize years after curative 
treatment. While ipsilateral adrenal metastasis is not uncommon, isolated contralateral adrenal metastasis (CAM) is 
extremely rare.   
Case Presentation: A 67-year-old Chinese man had history of Fuhrman Grade 2 right clear cell RCC (Stage 
T1bN0M0) with right radical nephrectomy done in 2014. Subsequently, he was diagnosed having prostatic 
carcinoma in 2016 with the Gleason score of 9 (4+5).  On staging CT for prostate cancer, left adrenal mass was 
noted, measuring 1.7cm x 3.0 cm x 2.5cm (AP x W x CC). He had further undergone Positron Emission Tomography 
(PET) scan which showed equivocal findings of a mildly hypermetabolic nodule in the left adrenal gland. In 
addition, there were 2 small hypermetabolic foci in the prostate gland compatible with prostate carcinoma and 
hypermetabolic mediastinal lymph nodes. Thus, strategy of surveillance for adrenal tumour was adopted. He was 
treated with radiotherapy and thereafter androgen deprivation therapy (ADT) with intramuscular Lucrin injection. 
However, the surveillance CT revealed that the left adrenal nodule increased in size. In view of progressive disease 
despite ADT, left adrenalectomy was done in 2017. Intra-operatively, there was a well-circumscribed, encapsulated 
left adrenal lesion with no invasion to surrounding tissue. Histopathological examination revealed metastatic clear 
cell RCC.  
Conclusion: Solitary CAM from RCC is extremely rare which will possibly occur at a remote interval following 
primary radical nephrectomy. Aggressive surgery remains as the feasible treatment option improving prognosis in 
such patients. 
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Introduction 
Renal Cell Carcinoma (RCC) is the most common kidney-originated neoplasm, which can be 
aggressive with high metastatic potential to any organ of the body. It spreads via hematogenous route. 
The common organs of metastasis are the lungs, liver, bones, lymph nodes and mediastinum [1]. In 
addition, it is reported that RCC can recur or metastasize years after curative treatment of the primary 
tumour. While ipsilateral adrenal metastasis is not uncommon due to its anatomical location, isolated 
contralateral adrenal metastasis is extremely rare. In one autopsy study of more than 400 patients who 
had undergone nephrectomy for RCC, there is only 2.5% found to have the contralateral adrenal gland 
as the sole site of metastasis [2].    
Case Presentation 
A 67-year-old Chinese man had history of Fuhrman Grade 2 right clear cell RCC (Stage 
T1bN0M0) with right radical nephrectomy done in 2014. The resected right adrenal gland was 
uninvolved. Subsequently, he complained of lower urinary tract symptoms (LUTS) with elevated 
Prostate-specific Antigen (PSA) and deranged renal profile in 2016, of which he was diagnosed having 
prostatic carcinoma with the Gleason score of nine (4+5).  On staging CT for prostate cancer, left 
adrenal mass was noted, measuring 1.7cm x 3.0 cm x 2.5cm (AP x W x CC). He had further undergone 
PET CT which showed equivocal findings of a mildly hypermetabolic nodule in the left adrenal gland. 
In addition, there were 2 small hypermetabolic foci in the prostate gland compatible with prostate 
carcinoma and hypermetabolic mediastinal lymph nodes. Thus, strategy of surveillance for adrenal 
tumour was adopted. He was treated with radiotherapy and thereafter androgen deprivation therapy 
(ADT) with intramuscular Lucrin injection. However, the surveillance CT revealed that the left adrenal 
nodule increased in size, which was measuring 3.2cm x 3.8cm x 4.7 cm (AP x W x CC). In view of 
progressive disease despite ADT, left adrenalectomy was done in 2017. Intra-operatively, there was a 
well-circumscribed left adrenal lesion with encapsulation with no capsular breach and invasion to 
surrounding tissue. Histopathological examination of the specimen revealed metastatic clear cell RCC. 
Up to the time of reporting, he remains asymptomatic while still on ADT. 
Discussion 
RCC has high metastatic potential to any organs of the body. Lung, bone, lymph nodes and 
liver are the commonest sites of metastasis in descending order of frequency. Adrenal gland metastasis 
is not uncommon based on the documented figure of 2-10% of clinical patients and 6-29% in autopsy 
series [1]. However, metachronous contralateral adrenal metastasis (CAM) is rare and possibly remote, 
as late as 23 years after primary nephrectomy [2]. It is reported that clear cell type has been nearly 
always isolated in isolated CAM, similar to this case [1]. The pathogenesis of this type of metastasis is 
still not clearly defined [2]. 
Although staging CT for prostate cancer noted left adrenal nodule in this patient, biopsy was 
not conducted due to technical difficulty after discussion with interventional radiologist. Moreover, the 
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matter was complicated with diagnosis of prostate cancer, which confused consultants on the cell 
origin of metastasis as well as the differential diagnosis of primary adrenal tumour. Multidisciplinary 
meeting between urologists, radiologists and oncologists had concluded that surveillance strategy to be 
adopted on top of the treatment as metastatic prostatic cancer.  
Removal of solitary metastatic lesion as in this case is the most feasible option because other 
treatments such as chemotherapy, hormonal therapy or radiotherapy are not proven effective [3]. The 
decision is based on the patient’s functional status, resectability and number of metastasis [1]. 
Complete clearance of isolated metastasis will increase 5-year survival rates. Plawner found out that 5-
year survival rate for the patients after resection of metachronous solitary CAM was 20%. This figure 
was much lower compared to those having synchronous adrenal metastasis, which was reported as 
40% [4]. In terms of operative strategy, the possibility of developing CAM after primary radical 
nephrectomy warrants the practice of adrenal-sparing radical nephrectomy whenever possible to 
prevent the risk of adrenal insufficiency if bilateral adrenals are involved [2].  
The incidence of prostate cancer was showed to be increased in patients with underlying 
known case of RCC. There could be a common etiological factor; however, the evidence is still scarce. 
Some had suggested that detection bias is the cause of the correlation [5]. This is because RCC 
patients who are followed-up by urologists may be prompted more vigorously or due to the incidental 
findings during staging. 
Conclusion 
Solitary CAM from RCC is extremely rare which will possibly occur at a remote interval 
following primary radical nephrectomy. Aggressive surgery remains as the feasible treatment option 
improving prognosis in such patients. The possibility of developing contralateral adrenal metastasis 
after primary radical nephrectomy supports the practice of adrenal-sparing radical nephrectomy 
whenever possible. We hereby present our case as a rare incidence of contralateral isolated adrenal 
metastasis from renal cell carcinoma.  
Consent 
The patient was informed to give his consent for image(s) and clinical information related to be 
reported in the Open Access Journal (both in print and online edition).  
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